Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Menter

Showing results (211-220 of 298) with videos related to

Pageof 30
Sort By:
JAMA|December 18, 2003
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trialKenneth B Gordon, Kim A Papp, Tiffani K Hamilton, et al.
Cutis|September 1, 2011
An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasisAlan Menter, Howard Sofen, Stacy Smith, et al.
Journal of the American Academy of Dermatology|September 30, 2019
Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.
The Journal of Dermatological Treatment|March 23, 2018
Prevalence of genital psoriasis in patients with psoriasisKim A P Meeuwis, Alison Potts Bleakman, Peter C M van de Kerkhof, et al.
International Journal of Dermatology|June 7, 2007
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb studyAlan Menter, Tiffani K Hamilton, Darryl P Toth, et al.
Journal of the American Academy of Dermatology|September 25, 2004
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trialAlice B Gottlieb, Robert Evans, Shu Li, et al.
Journal of Drugs in Dermatology : JDD|August 30, 2013
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label studyAlice B Gottlieb, Robert T Matheson, Alan Menter, et al.
Clinical Immunology (Orlando, Fla.)|April 20, 2004
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasisAlice B Gottlieb, Sewon Kang, Kenneth G Linden, et al.
International Journal of Dermatology|August 5, 2003
Ciclopirox gel for seborrheic dermatitis of the scalpRaza Aly, H Irving Katz, Steven E Kempers, et al.
International Journal of Dermatology|May 17, 2006
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trialKim A Papp, Reni Bressinck, Scott Fretzin, et al.
Pageof 30

Showing results (211-220 of 298) with videos related to

Sort By:
Pageof 30
JAMA|December 18, 2003
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trialKenneth B Gordon, Kim A Papp, Tiffani K Hamilton, et al.
Cutis|September 1, 2011
An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasisAlan Menter, Howard Sofen, Stacy Smith, et al.
Journal of the American Academy of Dermatology|September 30, 2019
Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.
The Journal of Dermatological Treatment|March 23, 2018
Prevalence of genital psoriasis in patients with psoriasisKim A P Meeuwis, Alison Potts Bleakman, Peter C M van de Kerkhof, et al.
International Journal of Dermatology|June 7, 2007
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb studyAlan Menter, Tiffani K Hamilton, Darryl P Toth, et al.
Journal of the American Academy of Dermatology|September 25, 2004
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trialAlice B Gottlieb, Robert Evans, Shu Li, et al.
Journal of Drugs in Dermatology : JDD|August 30, 2013
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label studyAlice B Gottlieb, Robert T Matheson, Alan Menter, et al.
Clinical Immunology (Orlando, Fla.)|April 20, 2004
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasisAlice B Gottlieb, Sewon Kang, Kenneth G Linden, et al.
International Journal of Dermatology|August 5, 2003
Ciclopirox gel for seborrheic dermatitis of the scalpRaza Aly, H Irving Katz, Steven E Kempers, et al.
International Journal of Dermatology|May 17, 2006
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trialKim A Papp, Reni Bressinck, Scott Fretzin, et al.
Pageof 30